Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment

Tu1158 Evaluating Adalimumab Drug and Antibody Levels As Predictors of Clinical and Laboratory Response in Crohn's Disease Patients

(2015) Yoav Mazor et al.   GASTROENTEROLOGY

490 Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between Ata and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients

(2015) Fernando S. Velayos et al.   GASTROENTEROLOGY

Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis

(2014) Der-Yuan Chen et al.   ANNALS OF THE RHEUMATIC DISEASES

A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis

(2014) Shigeto Kobayashi et al.   Modern Rheumatology

Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases

(2013) Xavier Roblin et al.   Clinical Gastroenterology and Hepatology

Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)

(2013) Pieter Dewint et al.   GUT

Phenotype of Inflammatory Bowel Disease at Diagnosis in the Netherlands

(2013) Veerle J. A. A. Nuij et al.   INFLAMMATORY BOWEL DISEASES

Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease

(2013) Yi-Lin Chiu et al.   INFLAMMATORY BOWEL DISEASES

Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease

(2013) Hirotsugu Imaeda et al.   JOURNAL OF GASTROENTEROLOGY

Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan

(2012) Tomoyuki Imagawa et al.   CLINICAL RHEUMATOLOGY

OC.06.5 RELATIONSHIP BETWEEN DRUG SERUM CONCENTRATION AND CLINICAL ACTIVITY IN PATIENTS WITH CROHN'S DISEASE WHO ACHIEVED REMISSION WITH ADALIMUMAB

(2012) G. Bodini et al.   DIGESTIVE AND LIVER DISEASE

High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy

(2011) Z. Zelinkova et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

(2011) E. Bultman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study

(2011) Suzanne Arends et al.   ARTHRITIS RESEARCH & THERAPY

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

(2010) Casper Steenholdt et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY